Business Wire

Queensland Residents in Australia Embrace Digital Driver Licences Powered and Protected by Thales

11.6.2024 10:00:00 EEST | Business Wire | Press release

Share

The Queensland Digital Licence App has reached over 500,000 users since its launch on 1 November, 2023, showing a clear appetite from Queensland residents for safe and secure digital identity. Thales and Queensland Department of Transport and Main Roads (TMR) released the new app to all Queensland residents following a successful pilot and an extended trial in Townsville, where engagement with real end users, businesses, and industry groups provided valuable insights to the project in readiness for the launch.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611475244/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Credit: Queensland Department of Transport and Main Roads

With core technology provided by Thales, supported by development and operations from local partners Code Heroes and Aliva, the QLD Digital Licence app is simple to use, secure, and designed with data security and user privacy in mind. The app includes features such as multi-factor authentication, integration with the Queensland Digital Identity (QDI) service, and built-in verification for secure user-to-user information exchange. The app's consent-based design gives the individual control over their identity data – users can present or share information from the app by selecting from common use cases that disclose only the relevant information for the transaction, such as ‘proof of age’, which displays an ‘over 18’ screen without exposing date of birth, address, or driving information – a popular feature. The app currently provides digital driver licences, proof of age (18+) cards, and marine licences, with the potential for more digital documents in future.

Businesses that need to check identity or age requirements to provide goods or services can download the standalone (QLD) Verifier for Digital Licence app, which electronically confirms the authenticity of data received from a Digital Licence app. Digital verification is also expected to help businesses reduce the need to store sensitive identity data attributes as the process of verification is quick and simple, allowing for point-in-time verification in a wide range of use cases. The requirements to develop verification functionality are publicly available within the mobile driving licence app standard (ISO/IEC18013-5), allowing the larger ecosystem to build complementary verification solutions and enhance the usability of the digital licence in everyday life.

The QLD Digital Licence app and Verifier for Digital Licence app developed by Thales, are available now to Queensland residents via the mobile app stores.

“Nothing is more important that your private data, which should be highly protected. We are proud of the current success of the Queensland Digital Licence app, ensuring the safety and security of private information while offering a modern digital experience. The app undergoes rigorous privacy and information security testing to protect identity. It aligns with international standards for mobile driver licences, setting the standard for mobile driver licence apps across Australia and the world” commentedMark Bailey, Minister for Transport and Main Roads.

“Through this collaboration, Thales demonstrates a field-proven capacity to provide citizens with highly convenient and secure solutions, allowing them to reap the full benefits of digitalization. The Queensland Digital Licence App is a significant milestone in the digital ID market, showing the growing importance of and appetite for alignment to international standards for mobile driving licences and interoperability across country borders” said Youzec Kurp, Senior Vice President Identity and Biometric Solutions at Thales.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.

It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.

Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

PLEASE VISIT

Thales Group
Digital Identity & Security

Thales
Thales Digital Identity and Security

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT

Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye